Startseite Medizin Pharmacist contributions in the treatment of diabetes mellitus in Southeast Asia: a narrative review
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Pharmacist contributions in the treatment of diabetes mellitus in Southeast Asia: a narrative review

  • Ayu Wulan Dwiputri ORCID logo , Liza Pristianty und Andi Hermansyah EMAIL logo
Veröffentlicht/Copyright: 23. Januar 2020

Abstract

Background

The growing burden of diabetes mellitus (DM) in Southeast Asia puts pharmacists in the ideal position to provide management of DM. This narrative review aims to describe the evidence of pharmacist contribution in improving DM in Southeast Asia.

Content

A literature search was conducted to identify relevant research articles published from 2010 to 2018 in four databases (Scopus, Pubmed, MEDLINE, and Springerlink) describing pharmacist roles and activities intended to improve management of DM in Southeast Asian countries. Results were synthesized narratively and divided into three main sections: (1) the role of pharmacist in DM management, (2) the impact of pharmacist role, and (3) the barriers to the implementation of services in DM management. A total of 16 studies were identified, of which ten studies mentioned services that were conducted exclusively by a pharmacist and the remaining collaborated with other health professionals. A number of pharmacist services were reported including prevention, dispensing, medication review, drug information services, patient counselling and education, monitoring, follow-up, and referral. Barriers related to individual, organizational, and public recognition were described.

Summary and outlook

The Pharmacist can contribute to improve DM management in a variety of settings. Action research on pharmacist intervention in DM is recommended.

  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

References

[1] World Health Organization (WHO). Global report on diabetes. 2016:21. Available at: http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=587D4B6F9513729EC30A29455BE78FAD?sequence=1. Accessed on 19 October 2019.Suche in Google Scholar

[2] International Diabetes Foundation (IDF). Diabetes atlas, 7th ed. 2015:50–2. Available at: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.html.Suche in Google Scholar

[3] Farland MZ, Byrd DC, McFarland MS, Thomas J, Franks AS, George CM, et al. Pharmacist-physician collaboration for diabetes care: the diabetes initiative program. Ann Pharmacother 2013;47:781–9.10.1345/aph.1S079Suche in Google Scholar PubMed

[4] Hughes J, Wibowo Y, Sunderalnd B, Hoti K. The role of the pharmacist in the management of type 2 diabetes: current insights and future directions. Integ Pharm Res Pract 2017;6:15–27.10.2147/IPRP.S103783Suche in Google Scholar PubMed PubMed Central

[5] FIP. Workforce report. 2012. Available at: http://apps.who.int/medicinedocs/en/m/abstract/Js20206en.Suche in Google Scholar

[6] Khunti N, Willies A, Davies M, Khunti K. The role of pharmacists in the management of type 2 diabetes: a literature review. Diabetes Prim Care 2013;15:131–40.Suche in Google Scholar

[7] Cipolle RJ, Strand LM, Morley PC, editors. Pharmaceutical care practice: the patient-centered approach to medication management, 3rd ed. New York: McGraw-Hill Education, 2012.Suche in Google Scholar

[8] World Health Organization. New tool to enhance role of pharmacists in health care. Geneva, Switzerland: WHO, 2006. Available at: http://bit.ly/CXEbm.Suche in Google Scholar

[9] World Health Organization. Adherence to long term therapies: evidence for action. 2003:7–9, 27–30. Available at: http://apps.who.int/medicinedocs/en/d/Js4883e/.Suche in Google Scholar

[10] Champbell RK. Role of the pharmacist in diabetes management. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 2002.Suche in Google Scholar

[11] Ayadurai S, Hattingh HL, Tee LB, Said SN. A narrative review of diabetes intervention studies to explore diabetes care opportunities for pharmacists. J Diabetes Res 2016;2016:5897452.10.1155/2016/5897452Suche in Google Scholar PubMed PubMed Central

[12] Anaya JP, Rivera JO, Lawson K, Garcia J, Luna J Jr, Ortiz M. Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health Syst Pharm 2008;65:1841–5.10.2146/ajhp070568Suche in Google Scholar PubMed

[13] Ramser KL, Sprabery LR, George CM, Hamann GL, Vallejo VA, Dorko CS, et al. Physician-pharmacist collaboration in the management of patients with diabetes resistant to usual care. Diabetes Spectrum 2008;21:209–14.10.2337/diaspect.21.3.209Suche in Google Scholar

[14] The American Pharmacists Association and The National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model. The American Pharmacists Association and The National Association of Chain Drug Stores Foundation, 2008.Suche in Google Scholar

[15] Wibowo Y, Parsons R, Sunderland B, Hughes J. An evaluation of community pharmacy-based services for type 2 diabetes in an Indonesian setting: patient survey. PeerJ 2015;3:e1449.10.7717/peerj.1449Suche in Google Scholar PubMed PubMed Central

[16] Keban SA, Najuah N, Syamsudin A. The role of pharmacists in evaluating and intervening the patients with diabetic neuropathy. Asian J Pharm Clin Res 2017;10:127–31.10.22159/ajpcr.2017.v10i2.14796Suche in Google Scholar

[17] Adikusuma W, Nurul Q. Adherence level and blood sugar control of type 2 diabetes mellitus patients who gets counseling and short messages service as reminder and motivation. Asian J Pharm Clin Res 2018;11:219–22.10.22159/ajpcr.2018.v11i2.22988Suche in Google Scholar

[18] Siaw MY, Ko Y, Malone DC, Tsou KY, Lew YJ, Foo D, et al. Impact of pharmacist-involved collaborative care on the clinical, humanistic and cost outcomes of high-risk patients with type 2 diabetes (IMPACT): a randomized controlled trial. J Clin Pharm Ther 2017;42:475–82.10.1111/jcpt.12536Suche in Google Scholar PubMed

[19] Siaw MY, Jing HT, Joyce Y, Chia L. Patients’ perceptions of pharmacist‑managed diabetes services in the ambulatory care and community settings within Singapore. Int J Clin Pharm 2018;40:403–11.10.1007/s11096-018-0591-2Suche in Google Scholar PubMed

[20] Lim PC, Lim K. Evaluation of a pharmacist-managed diabetes medication therapy adherence clinic. Pharm Pract (Granada) 2010;8:250–4.10.4321/S1886-36552010000400008Suche in Google Scholar

[21] Huri HZ, Lee CL. Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia. BMC Public Health 2013;13:1192.10.1186/1471-2458-13-1192Suche in Google Scholar PubMed PubMed Central

[22] Chung WW, Chua SS, Lai PS, Chan SP. Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes. Patient Prefer Adher 2014;8:1185–94.10.2147/PPA.S66619Suche in Google Scholar PubMed PubMed Central

[23] Chan HK, Mohamed AH. Modified labels for long-term medications: influences on adherence, comprehension and preferences in Malaysia. Int J Clin Pharm 2014;36:904–13.10.1007/s11096-014-0003-1Suche in Google Scholar PubMed

[24] Butt M, Adliah Ali M, Mohd MB, Norlaila M. Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: a randomised controlled study. Saudi Pharm J 2016;24:40–8.10.1016/j.jsps.2015.02.023Suche in Google Scholar PubMed PubMed Central

[25] Lim PC, Lim K, Embee ZC, Hassali MA, Thiagarajan A, Khan TM. Study investigating the impact of pharmacist involvement on the outcomes of diabetes medication therapy adherence program Malaysia. Pak J Pharm Sci 2016;29:595–601.Suche in Google Scholar

[26] Lee EL, Wong PS, Tan MY, Sheridan J. What role could community pharmacists in Malaysia play in diabetes self-management education and support? The views of individuals with type 2 diabetes. Int J Pharm Pract 2018;26:138–49.10.1111/ijpp.12374Suche in Google Scholar PubMed

[27] Chua SS, Kok LC, Yusof FA, Tang GH, Lee SW, Efendie B, et al. Pharmaceutical care issues identified by pharmacists in patients with diabetes, hypertension or hyperlipidaemia in primary care settings. BMC Health Serv Res 2012;12:388.10.1186/1472-6963-12-388Suche in Google Scholar PubMed PubMed Central

[28] Dhippayom T, Anjana F, Sirirat T, Nathorn C. Opportunistic screening and health promotion for type 2 diabetes: an expanding public health role for the community pharmacist. J Public Health 2012;35:262–9.10.1093/pubmed/fds078Suche in Google Scholar PubMed

[29] Saengcharoen W, Rita M, Sanguan L. Assessment of multimedia-supported intervention in Muslim diabetic patients treated with insulin. Int J Diabetes Dev Ctries 2016;36:327–33.10.1007/s13410-015-0463-4Suche in Google Scholar

[30] Otgontuya D, Sophal O, Enkhtuya P, Manju R, Brian SB. Individual-based primary prevention of cardiovascular disease in Cambodia and Mongolia: early identification and management of hypertension and diabetes mellitus. BMC Public Health 2012;12:254.10.1186/1471-2458-12-254Suche in Google Scholar PubMed PubMed Central

[31] Fathelrahman AI, Mohamed IM, Albert IW. Pharmacy practice in developing countries: achievements and challenges. London: Elsevier, 2013.Suche in Google Scholar

[32] Mammen NG, Kurt EH, Markus M, Salja L, Nej H, Foppe, Mitja K. PCNE definition of medication review: reaching agreement. Int J Clin Pharm 2018;40:1199–1208.10.1007/s11096-018-0696-7Suche in Google Scholar PubMed

[33] Blenkinsopp A, Bond C, Raynor DK. Medication reviews. Br J Clin Pharmacol. 2012;74:573–80.10.1111/j.1365-2125.2012.04331.xSuche in Google Scholar PubMed PubMed Central

[34] Pharmaceutical Care Network Europe Foundation (PCNE). PCNE classification for drug-related problems version 5.01. 2006. Available at: http://www.pcne.org/sig/drp/documents/PCNE%20classification%20V5.01.pdf.Suche in Google Scholar

[35] Kemenkes RI (Indonesian Ministry of Health). Peraturan Menteri Kesehatan Nomor 73 Tahun 2016: Standar Layanan Kefarmasian di Apotek (Minister of Health Regulation Number 73 In 2016: Standards for Pharmaceutical Care In Community Pharmacies). Jakarta: KemenkesRI, 2016.Suche in Google Scholar

[36] Malaysian Ministry of Health. Management of type 2 diabetes mellitus. 2013. Available at: http://www.moh.gov.my/attachments/3878.pdf.Suche in Google Scholar

[37] American Association of Diabetes Educators (AADE). AADE7– self-care behaviors: American Association of Diabetes Educators (AADE) position statement. 2014. Available at: https://www.diabeteseducator.org/docs/default-source/practice/practice-resources/position-statements/aade7-self-care-behaviors-position-statement.pdf?sfvrsn=6Suche in Google Scholar

[38] American Diabetes Association (ADA). Standards of medical care in diabetes. Diabetes Care 2013;36(Suppl 1):S11–66.10.2337/dc13-S011Suche in Google Scholar PubMed PubMed Central

[39] Hermansyah A, Erika S, Ines K. Investigating the impact of the universal healthcare coverage programme on community pharmacy practice. Health Soc Care Community 2018;26:e249–60.10.1111/hsc.12506Suche in Google Scholar PubMed

[40] Tang TS, Funnell MM, Noorulla S, Oh M, Brown MB. Sustaining short-term improvements over the long-term: results from a 2-year diabetes self-management support (DSMS) intervention. Diabetes Res Clin Pract 2012;95:85–92.10.1016/j.diabres.2011.04.003Suche in Google Scholar PubMed PubMed Central

[41] American Diabetes Association (ADA). Standards of medical care in diabetes. USA: The American Diabetes Association, Inc., 2018.Suche in Google Scholar

[42] Hermansyah A, Erica S, Ines K. Community pharmacy and emerging public health initiatives in developing Southeast Asian countries: a systematic review. Health Soc Care Community 2016;24:e11–22.10.1111/hsc.12289Suche in Google Scholar PubMed

[43] Athiyah U, Catur DS, Gesnita N, Elida S, Wahyu U. Assessment of pharmacists’ knowledge, attitude and practice in chain community pharmacies towards their current function and performance in Indonesia. Pharm Pract 2019;17:1518.10.18549/PharmPract.2019.3.1518Suche in Google Scholar PubMed PubMed Central

Received: 2019-10-31
Accepted: 2019-11-22
Published Online: 2020-01-23

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Reviews
  2. Pharmacist contributions in the treatment of diabetes mellitus in Southeast Asia: a narrative review
  3. The implementation of a chronic disease management program (Prolanis) in Indonesia: a literature review
  4. Original Articles
  5. Quercetin attenuates acute predator stress exposure-evoked innate fear and behavioral perturbation
  6. Evaluating current practices and policies in the use of injectable medicines for treating myalgia in a primary care center in Pamekasan, Indonesia
  7. The contemporary role and potential of pharmacist contribution for community health using social media
  8. Evaluation of rational drug use based on World Health Organization prescribing indicators in a primary care center in Pamekasan East Java, Indonesia
  9. The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting
  10. Factors affecting community pharmacist’s service for women with chronic diseases during pregnancy and breastfeeding: application of the Health Belief Model
  11. Overview of therapeutic changes in antiepileptic drugs in adult patients
  12. Exploration of barriers affecting job satisfaction among community pharmacists
  13. Patients’ characteristics and their adherence to insulin therapy
  14. Correlation of chemotherapy costs with quality of life in nasopharyngeal cancer patients
  15. Impact of educational preeclampsia prevention booklet on knowledge and adherence to low dose aspirin among pregnant women with high risk for preeclampsia
  16. Translation, cultural adaptation, and validation of the quality of well being self-administered questionnaire in general population in Indonesia
  17. Knowledge, attitude, and practice of pharmacists towards management of hypertension in primary care centers
  18. Medication adherence in diabetes mellitus patients at Tanjung Karang Primary Health Care Center, Mataram
  19. Decreasing angiogenesis vasa vasorum through Lp-PLA2 and H2O2 inhibition by PSP from Ganoderma lucidum in atherosclerosis: in vivo diabetes mellitus type 2
  20. Antiaggregation effect of clopidogrel in coronary heart disease patients using omeprazole
  21. The effect of curcuma (Curcuma xanthorrizha roxb.) extract as an adjuvant of captopril therapy on cardiac histopathology of male mice (Mus musculus) with hypertension
  22. Coenzyme Q10 nanostructured lipid carriers as an inducer of the skin fibroblast cell and its irritability test in a mice model
  23. Medical problems in patients with chronic kidney disease undergoing hemodialysis and their therapy
  24. ADMET properties of novel 5-O-benzoylpinostrobin derivatives
  25. Development of nonalcoholic fatty liver disease model by high-fat diet in rats
  26. Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor
  27. The relationship between the level of education and accuracy of insulin injection techniques in DM patients with measurement of HbA1c values
  28. The effect of premixed insulin to blood glucose concentration in patients with type 2 diabetes mellitus
  29. Intravenous insulin therapy in diabetes mellitus with hyperglycemic crisis and intercurrent illness
  30. Adherence behavior assessment of oral antidiabetic medication use: a study of patient decisions in long-term disease management in primary health care centers in Surabaya
  31. Evaluation to the chemotherapy use in patients with diffuse large B-cell lymphoma
  32. Analysis of the use and cost of stress ulcer prophylaxis for surgical inpatients
  33. Antineuroinflammation activity of n-butanol fraction of Marsilea crenata Presl. in microglia HMC3 cell line
  34. The enhancement of Arg1 and activated ERβ expression in microglia HMC3 by induction of 96% ethanol extract of Marsilea crenata Presl. leaves
  35. Ternary solid dispersion to improve solubility and dissolution of meloxicam
  36. Improving solubility and dissolution of meloxicam by solid dispersion using hydroxypropyl methylcellulose 2910 3 cps and nicotinamide
  37. o-Hydroxycinnamic derivatives as prospective anti-platelet candidates: in silico pharmacokinetic screening and evaluation of their binding sites on COX-1 and P2Y12 receptors
  38. The change of proinflammatory cytokine tumor necrosis factor α level in the use of meloxicam in rat model of osteoarthritis
  39. Attenuation of IL-1ß on the use of glucosamine as an adjuvant in meloxicam treatment in rat models with osteoarthritis
  40. Analysis of effectiveness and drug related problems of pain reliever for knee osteoarthritis: weighing clinical risk and benefit
  41. Comparison of antibiotic prescriptions in adults and children with upper respiratory tract infections in Bangka Tengah primary health care centers
  42. Profile of sociodemographics, sources of infection, antiretrovirals and CD4 counts on HIV/AIDS outpatients in Turen Primary Health Centre, Indonesia
  43. Synergistic anti-hepatitis C virus activity of Ruta angustifolia extract with NS3 protein inhibitor
  44. In vitro equivalence of generic and branded amoxicillin tablet by microbiological assay method
  45. Knowledge and attitude: two fundamental factors that determine patient compliance in antibiotic therapy
  46. Molecular docking study of sappan wood extract to inhibit PBP2A enzyme on methicillin-resistant Staphylococcus aureus (MRSA)
  47. Effect of curcumin analogue synthetic product from cullilawan oil for the liver damage treatment in male mice (Mus musculus L.)
  48. Case Report
  49. A case report of generalized tetanus in a 42-year-old man with dental infection
Heruntergeladen am 14.12.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2019-0322/html?lang=de
Button zum nach oben scrollen